Literature DB >> 21030382

The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab.

L H J Simkens1, J Tol1, L W M M Terstappen2, S Teerenstra3, C J A Punt1, I D Nagtegaal4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21030382     DOI： 10.1093/annonc/mdq640

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  15 in total

1.  Circulation of progenitor cells in obese and lean colorectal cancer patients.

Authors:  Charles F Bellows; Yan Zhang; Jinyun Chen; Marsha L Frazier; Mikhail G Kolonin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-19       Impact factor: 4.254

Review 2.  Challenges in circulating tumor cell detection by the CellSearch system.

Authors:  Kiki C Andree; Guus van Dalum; Leon W M M Terstappen
Journal:  Mol Oncol       Date:  2015-12-25       Impact factor: 6.603

3.  Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.

Authors:  Fadi Najjar; Moosheer Alammar; Marroan Bachour; Nissreen Almalla; Moaz Altahan; Ali Alali; Ghassan Al-Massarani
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-19       Impact factor: 4.553

4.  Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.

Authors:  N Beije; J Kraan; W Taal; B van der Holt; H M Oosterkamp; A M Walenkamp; L Beerepoot; M Hanse; M E van Linde; A Otten; R M Vernhout; F Y F de Vos; J W Gratama; S Sleijfer; M J van den Bent
Journal:  Br J Cancer       Date:  2015-06-04       Impact factor: 7.640

5.  Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.

Authors:  Christina Leah B Kline; Wafik S El-Deiry
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-21

6.  Prognostic value of circulating endothelial cells in metastatic colorectal cancer.

Authors:  Nuh N Rahbari; Sebastian Schölch; Ulrich Bork; Christoph Kahlert; Martin Schneider; Mohammad Rahbari; Markus W Büchler; Jürgen Weitz; Christoph Reissfelder
Journal:  Oncotarget       Date:  2017-06-06

7.  Targeted therapies in colorectal cancer-an integrative view by PPPM.

Authors:  Suzanne Hagan; Maria C M Orr; Brendan Doyle
Journal:  EPMA J       Date:  2013-01-28       Impact factor: 6.543

8.  The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon.

Authors:  Pierre L Triozzi; Susan Achberger; Wayne Aldrich; Arun D Singh; Ronald Grane; Ernest C Borden
Journal:  J Transl Med       Date:  2012-12-05       Impact factor: 5.531

9.  Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.

Authors:  Lucia Cuppini; Angelica Calleri; Maria Grazia Bruzzone; Elena Prodi; Elena Anghileri; Serena Pellegatta; Patrizia Mancuso; Paola Porrati; Anna Luisa Di Stefano; Mauro Ceroni; Francesco Bertolini; Gaetano Finocchiaro; Marica Eoli
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

Review 10.  The Blood Circulating Rare Cell Population. What is it and What is it Good For?

Authors:  Stefan Schreier; Wannapong Triampo
Journal:  Cells       Date:  2020-03-25       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.